VSW1198
VSW1198 is an inhibitor for geranylgeranyl diphosphate synthase (GGDPS) with an IC50 of 45 nM. VSW1198 reveals antitumor activity in myeloma- and prostate cancer with liver toxicity.
For research use only. We do not sell to patients.
- Formula: C15H23N3Na4O6P2
- Molecular Weight:495.27
-
Storage:
Please store the product under the recommended conditions in the Certificate of Analysis.
Biological Activity
Description
IC50 & Target
IC50: 45 nM (GGDPS)
Cellular Effect
|
Cell Line
|
Type | Value | Description | References |
|---|---|---|---|---|
| RPMI-8226 | EC50 |
0.19 μM
Compound: 8
|
Cytotoxicity against human RPMI8226 after 48 hrs by MTT assay
Cytotoxicity against human RPMI8226 after 48 hrs by MTT assay
|
[PMID: 26713103] |
Chemical Information
-
Molecular Weight 495.27
-
Formula C15H23N3Na4O6P2
-
SMILES
O=P(O[Na])(O[Na])C(P(O[Na])(O[Na])=O)CC1=CN(CC/C=C(C)/CC/C=C(C)/C)N=N1
-
Shipping
Room temperature in continental US; may vary elsewhere.
-
Storage
Please store the product under the recommended conditions in the Certificate of Analysis.
Protocols
-
Cell Cytotoxicity Assay
Cytotoxicity assays are usually based on the assessment of cell membrane damage, which can also be indirectly detected by measuring cell viability. Detection methods include MTT assay, CKK-8 assay, LDH assay and ATP assay, etc.
-
Hepatotoxicity Study
This protocol evaluates hepatotoxicity using complementary in vivo mouse APAP acute liver injury and in vitro hepatocyte-based cytotoxicity readouts. In vivo APAP injury is assessed by serum ALT/AST, liver histology, hepatic glutathione, protein adducts, necrosis, inflammation, and regeneration-related endpoints. In vitro hepatotoxicity is assessed by loss of viability, leakage of ALT/AST/LDH, oxidative-stress markers, mitochondrial function, nuclear morphology, intracellular calcium, and high-content imaging endpoints.
-
Subcutaneous Cell-Line-Derived Xenograft
Subcutaneous cell-line-derived xenograft (CDX) models are established by implanting cultured human cancer cell lines into immunodeficient mice, where the injected cells form localized tumors that can be monitored in vivo as a measure of tumorigenic potential, growth kinetics, and treatment response. These models are widely used in oncology research because they allow reproducible tumor formation and enable comparative assessment of tumor growth between different cell lines or genetic manipulations in a controlled in vivo microenvironment. Subcutaneous implantation of cancer cells in immunodeficient mice is a standard approach for evaluating tumor growth behavior and therapeutic response across multiple cancer types, including prostate, esophageal, pancreatic, and colon cancer models.
Purity & Documentation
References
Calculators
Concentration (start) × Volume (start) = Concentration (final) × Volume (final)